The candidate TB vaccine, MVA85A, induces highly durable Th1 responses by Tameris, Michele et al.
The Candidate TB Vaccine, MVA85A, Induces Highly
Durable Th1 Responses
Michele Tameris1*, Hennie Geldenhuys1, Angelique KanyKany Luabeya1, Erica Smit1, Jane E. Hughes1,
Samantha Vermaak2, Willem A. Hanekom1, Mark Hatherill1, Hassan Mahomed1, Helen McShane2.,
Thomas J. Scriba1.
1 South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town,
Cape Town, South Africa, 2 Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
Abstract
Background: Vaccination against tuberculosis (TB) should provide long-term protective immunity against Mycobacterium
tuberculosis (M.tb). The current TB vaccine, Bacille Calmette-Guerin (BCG), protects against disseminated childhood TB, but
protection against lung TB in adolescents and adults is variable and mostly poor. One potential reason for the limited
durability of protection may be waning of immunity through gradual attrition of BCG-induced T cells. We determined if a
MVA85A viral-vector boost could enhance the durability of mycobacteria-specific T cell responses above those induced by
BCG alone.
Methods: We describe a long-term follow-up study of persons previously vaccinated with MVA85A. We performed a
medical history and clinical examination, a tuberculin skin test and measured vaccine-specific T cell responses in persons
previously enrolled as adults, adolescents, children or infants into three different Phase II trials, between 2005 and 2011.
Results: Of 252 potential participants, 183 (72.6%) consented and completed the study visit. Vaccine-induced Ag85A-
specific CD4+ T cell responses were remarkably persistent in healthy, HIV-uninfected adults, adolescents, children and
infants, up to 6 years after MVA85A vaccination. Specific CD4+ T cells expressed surface markers consistent with either
CD45RA2CCR7+ central memory or CD45RA2CCR72 effector memory T cells. Similarly durable Ag85A-specific CD4+ T cell
responses were detected in HIV-infected persons who were on successful antiretroviral therapy when MVA85A was
administered. By contrast, Ag85A-specific CD4+ T cell frequencies in untreated MVA85A-vaccinated HIV-infected persons
were mostly undetectable 3–5 years after vaccination.
Conclusion: MVA85A induces remarkably durable T cell responses in immunocompetent persons. However, results from a
recent phase IIb trial of MVA85A, conducted in infants from the same geographic area and study population, showed no
vaccine efficacy, suggesting that these durable T cell responses do not enhance BCG-induced protection against TB in
infants.
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Introduction
Despite all efforts, tuberculosis (TB) remains a major global
problem, especially in Sub-Saharan Africa and Asia. Approxi-
mately 1.45 million people died from TB in 2011 [1]. It is clear
that better intervention strategies against TB are urgently
required. Epidemiological modelling suggests that global TB
elimination targets can only be achieved with an effective
vaccination strategy, coupled with better diagnosis and more
effective treatment of persons with TB disease [2,3].
Most researchers recognise that vaccination against TB should
aim to induce a specific T cell response. However, it is not known
which characteristics of a T cell response may mediate protection
against TB [4,5]. Vaccination with Bacille Calmette-Guerin
(BCG) confers good protection against disseminated childhood
TB, but provides variable protection against pulmonary disease,
especially in adolescents and adults [6,7]. One possible reason
underlying limited protection beyond childhood is waning of
BCG-induced immunity against TB through gradual attrition of
BCG-induced T cell responses [8].
Successful prophylactic vaccines, such as those against tetanus
toxoid [9], yellow fever [10] and smallpox [11] induce protective
immunity that persists for decades. We proposed that vaccination
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against TB should aim to induce similarly long-lived immunity, in
the form of mycobacteria-specific memory T cells. A heterologous
prime–boost vaccination strategy may potentially improve the
longevity of the BCG-induced T cell response. We sought to
determine if a BCG-prime viral-vector vaccine boost strategy
against TB, with Modified Vaccinia virus Ankara expressing the
mycobacterial antigen Ag85A (MVA85A), could enhance the
durability of mycobacteria-specific T cell responses above those
induced by BCG alone. The MVA85A vaccine showed promising
immunogenicity and induced protective immunity against M.tb in
cattle [12], rhesus macaques [13], mice [14] and guinea pigs [15].
Phase I and IIa clinical trials of MVA85A have been conducted in
healthy adults, adolescents and children from the United
Kingdom, the Gambia, South Africa and Senegal [16–25]. Adult
participants have included HIV infected people, both on
antiretroviral (ARV) therapy and ARV naı¨ve, and M.tb-infected
participants. MVA85A was shown to be well tolerated in these
different clinical populations from different settings. Further, the
vaccine induced robust Ag85A-specific CD4 T cells responses,
which predominantly expressed IFN-c, TNF-a and IL-2, in
vaccinees of all ages. However, a recent phase IIb proof-of-concept
trial in South African infants showed no efficacy against TB [26].
Current approaches to clinical evaluation of novel TB vaccines,
such as the ones listed above, typically limit follow-up of
vaccinated participants to 6 or perhaps 12 months, precluding
evaluation of long-lived immunity. We conducted a long-term
follow-up (3–6 years) of persons who received MVA85A as a boost
vaccine to routine BCG vaccination at birth. We re-enrolled
previous participants of three phase I/IIa trials conducted between
2005 and 2011 in the Western Cape Province of South Africa, a
setting where TB is endemic, and performed a medical history and
clinical examination, a tuberculin skin test (TST) and measured
the frequencies, phenotypes and cytokine expression profiles of
antigen-specific T cell responses.
Materials and Methods
Study Design and Population
This was a descriptive cross-sectional study of the safety and
immune responses induced by MVA85A in previous participants
of phase I and II trials of MVA85A [17,22–24]. These trials were
conducted between 2005 and 2011 at the South African TB
Vaccine Initiative Field Site in the Western Cape Province of
South Africa. Previous participants included 24 healthy adults [17]
and 12 healthy adolescents [22] enrolled into the TB008 trial
(clinicaltrials.gov NCT00460590), 48 M.tb and/or HIV-infected
adults enrolled into the TB011 trial (clinicaltrials.gov
NCT00480558) [24] and 24 healthy children [22] and 144
healthy infants [23] enrolled into the TB014 trial (clinicaltrials.gov
NCT00679159). All three trials were open label; in trial TB014
one in four infants was allocated to receive PrevenarH as a placebo
control, instead of MVA85A. All participants except one in trial
TB014 had completed per-protocol follow up, which was 12
months in TB008 and TB011 and 6 months in TB014. Previous
participants or their parents/legal guardians were approached to
participate in this follow up study. Written informed consent and
assent, if the participant was a minor between 7 and 17 years old,
were obtained in the participant’s home language. Study
procedures included a targeted medical history and examination,
phlebotomy, and administration of a tuberculin skin test (TST,
Mantoux method). Consent for participation included granting
access to participant medical records including CD4+ T cell count
and viral load records for trial TB011 participants. The TST was
read after 48–72 hours at the participant’s home, school or
workplace using a transparent ruler to measure the largest
transverse diameter [27]. For consistency with TST cut-offs with
previous trials, we defined TST indurations of.15 mm as positive
in adults and adolescents who were previous participants of trial
TB008 [17,22], whereas TST indurations of $10 mm were
defined as positive in children, infants and M.tb- infected and/or
HIV-infected adults who were participants of trials TB011 and
TB014 [23,24].
This study was approved by the University of Cape Town
Health Sciences Faculty Human Research Ethics Committee
(UCT FHS HREC) and the Oxford University Tropical Research
Ethics Committee (OxTREC). All investigations were conducted
according to the principles expressed in the Declaration of
Helsinki.
IFN-c ELISpot assay
Antigens included a single pool of peptides spanning the Ag85A
protein (15-mers, overlapping by 10 amino acids, each at 2 mg/
mL; Peptide Protein Research Ltd) and live BCG (from the
vaccine vial, strain SSI, Staten Serum Institute, 1.26106 CFU/
mL), prepared as previously described [22]. A peptide pool
spanning the M.tb-specific antigens ESAT-6 and CFP-10 (15-mers,
overlapping by 10 amino acids; 2 mg/mL each, Peptide Protein
Research Ltd) was also included. Medium alone served as negative
control and phytohemagglutinin (PHA, Sigma-Aldrich, 10 mg/
mL) as positive control. Plates, containing 36105 peripheral blood
mononuclear cells (PBMC) per well, were incubated for 18 hours
at 37uC and developed according to the manufacturer’s protocol
(Mabtech). Assays were performed in duplicate wells and the
average (with background subtracted) was used for analysis. The
cut-off for positive responses was 50 spot forming cells (SFC) per
million PBMC [22].
Whole blood intracellular cytokine staining
Briefly, 0.5 mL heparinized whole blood was incubated
immediately after collection with antigens in the presence of
anti-CD28 and anti-CD49d (0.5 mg/mL each, BD Biosciences).
After 7 hours, Brefeldin A (Sigma-Aldrich) was added and samples
were incubated for a further five hours. A single pool of Ag85A
peptides (2 mg/mL per peptide) and BCG (1.26106 CFU/mL)
were used as antigens. No antigen (co-stimulant antibodies only)
was used as negative control and PHA (10 mg/mL,) as positive
control. Erythrocytes were lysed and white cells fixed using
FACSLysing Solution (BD Biosciences), before cryopreservation.
Cells were thawed in batch, permeabilized with BD Perm/Wash
buffer and stained with fluorescent antibodies. Antibodies for
detecting cytokine responses by CD4+ and CD8+ T cells were as
follows: CD3-Pacific Blue (UCTH1), CD8-PerCPCy5.5 (SK1),
CCR7-PE (150503), IFN-c-AlexaFluor700 (K3), IL-2-FITC
(5344.111, all from BD Biosciences), TNF-a-PECy7 (MAb11),
IL-17-AlexaFluor647 (eBio64CAP17, both from eBiosciences),
CD45RA-BV570 (HI100, Biolegend) and CD4-QDot605 (SK3,
Invitrogen). At least 1 million total cells were acquired on an LSR
II flow cytometer (BD Biosciences). Cell doublets were excluded
using forward scatter (FSC)–area versus FSC-height parameters.
Single stained mouse k beads were used to calculate compensa-
tions for every run.
Statistical analyses
Descriptive statistics were used to analyse medical history and
clinical examination. TST conversion was reported as either
conversion from a negative to positive induration using original
trial protocol–defined cut-offs (Table 1), or conversion from a
negative to positive induration plus an increase in induration of
Durable Th1 Responses with MVA85A
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$6 mm in trials TB008 and TB014. For each sub-group we
recorded the occurrence of TB disease from the medical history
and rates of M.tb infection, measured by IFN-c ELISpot responses
to ESAT-6 and CFP-10. A cut-off of 50 spot forming units (SFU)
per million PBMC was considered positive, as previously described
[17].
Data analysis was performed with FlowJo software version 9.0
(TreeStar). The Boolean gate platform was used with individual
cytokine gates to create all possible response pattern combinations.
The data analysis programs PESTLE (version 1.5.4) and SPICE
(Simplified Presentation of Incredibly Complex Evaluations;
version 4.1.6) were used to analyse flow cytometry data and
generate graphical representations of T cell responses using
background-deducted flow cytometric data (both kindly provided
by Mario Roederer, Vaccine Research Center, NIAID, NIH).
Statistical tests were performed using Prism version 4.03
(GraphPad). T cell responses at different time points were
compared using Kruskal-Wallis (overall effect) and Mann-Whitney
U tests. Paired comparisons of immune responses at individual
pre- or post-vaccination time points were done using the Wilcoxon
Matched Pairs test.
Results
Participants
Of the 252 participants of the previous phase I/II MVA85A
vaccine trials, 182 (72.2%) were located and enrolled into this
long-term follow-up study.
Seventeen of 24 (70.8%) adults from trial TB008 were re-
enrolled at a median of 5.7 years since MVA85A vaccination
(range 5.3–6.1 years), while nine of 12 (75%) adolescents were re-
enrolled at a median of 4.6 years (range 4.4–4.8 years) post-
vaccination (Table 1). One hundred and nineteen (70.8%) of the
168 TB014 participants were located and enrolled, including 16
(66.6%) of 24 children and 103 of 144 (71.5%) infants. The infants
were distributed across three groups who received increasing
MVA85A doses, and a placebo control group, who received
PrevenarH, as laid out in Table 1.
Of the 48 trial TB011 participants, 37 (77.1%) were located and
enrolled (Table 1). These included 11 (91.6%) from Group 1
(M.tb-infected, HIV-negative), eight (66.7%) from Group 2 (M.tb-
uninfected, HIV-infected), nine (75%) from Group 3 (M.tb and
HIV co-infected) and nine (75%) from Group 4 (HIV-infected and
stable on antiretroviral therapy (ARV); +/2 M.tb infection).
Follow-up time since MVA85A vaccination ranged from 1.9 to 4.3
years (Table 1).
Health Assessment
Nine healthy babies were born to participants of the TB008 [17]
and TB011 [24] trials since the final trial study visit. No
hospitalisations or visits to a health facility for a condition possibly,
probably or definitely related to the study vaccine were reported
for any participants of the TB008 trial. None of the TB008
participants had been prescribed TB treatment since the trial. One
adult and two adolescents may have acquired M.tb-infection as
they recorded a TST reading exceeding 15 mm, the cut-off for
M.tb infection in the TB008 trial. The increase in TST induration
for these two adolescents was $6 mm.
Seven of the participants who previously enrolled as infants into
the TB014 trial had received TB treatment since the final clinical
trial visit: two in Group 1, one each in Groups 2 and 3, and three
in the PrevenarH group. A total of 6participants who previously
enrolled as infants received TB prophylaxis; one in each of Group
1 and 2, two in Group 3, and two Prevenar recipients received TB
prophylaxis. TST conversion to .10 mm was reported in one of
the older children, two participants each of infant Groups 1 and 2,
four in Group 3 and none in the PrevenarH group (p = 0.06).
One participant in TB011 Group 4, who had a negative TST
during the original trial, converted to a positive TST. A single
participant in Group 2 and one in Group 3 had commenced TB
treatment since the last study visit, while three Group 2
participants and three Group 3 participants had initiated
antiretroviral therapy. All HIV-positive participants showed
continued immunologic and virologic control as measured by
CD4+ T cell counts and HIV RNA load. Two deaths had
occurred in HIV-infected participants (Group 2), one due to
uncontrolled epilepsy and one due to unknown natural causes.
These were not considered related to the study vaccine.
MVA85A-induced Ag85A-specific T cell responses are
remarkably durable
To determine if MVA85A-induced immune responses persisted
for years, we measured the magnitude of Ag85A-specific T cell
responses by IFN-c ELISpot assay in peripheral blood collected 3–
6 years after MVA85A vaccination. The MVA85A vaccine trials
in adults, adolescents and children did not include placebo groups,
precluding comparison of response durability in vaccinated and
unvaccinated groups. We therefore compared response magni-
tudes detected after long-term follow-up with those detected before
MVA85A vaccination. Frequencies of Ag85A-specific IFN-c-
expressing T cells detected 3 to 6 years after MVA85A vaccination
of adults, adolescents, children and infants were still significantly
higher than those detected before vaccination (Figure 1A–D and
Table S1). Because the study design for the TB014 infant trial
included a placebo group (PrevenarH), we also compared
magnitudes of Ag85A-specific T cells detected in each vaccine
dose group to the placebo group. Frequencies of IFN-c-expressing
Ag85A-specific T cells detected 63 years after vaccination with
either 2.56107, 56107 or 106107 plaque-forming units (pfu) of
MVA85A significantly exceeded those detected in placebo
recipients, most of whom had undetectable Ag85A-specific T cell
responses (Figure 1E).
Given the high levels of exposure to M.tb in the TB endemic
setting where these trials were conducted, we reasoned that
Ag85A-specific immune responses may have been augmented in
study participants who had acquired M.tb infection since the
original vaccine trials. We therefore excluded participants with
positive IFN-c ELISpot responses to ESAT-6/CFP-10 from these
analyses (persons found to be M.tb-infected at screening were
excluded from the original TB008 and TB014 trials). Frequencies
of Ag85A-specific T cells after long-term follow-up of adults,
children and infants without M.tb infection were still significantly
higher than those detected before vaccination (red p-values in
Figure 1A, C–E). Only two participants in the adolescent group
remained uninfected; comparison of responses in uninfected
persons within this group was therefore not possible (Figure 1B).
Persistent Ag85A-specific CD4 T cells are mostly
polyfunctional
We previously showed that Ag85A-specific CD4+ T cells
detected 6–12 months after MVA85A vaccination in adolescents,
children and infants were predominantly polyfunctional, co-
expressing the Th1 cytokines IFN-c, TNF-a, and IL-2 [22,23].
To determine if this cytokine expression profile changed over time,
we characterised the cytokine expression profile of persistent
Ag85A-specific CD4+ T cells by flow cytometry (Figure S1 and
Figure 2). Ag85A-specific T cells detected 3–6 years after
Durable Th1 Responses with MVA85A
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MVA85A vaccination of adolescents predominantly resided in the
IFN-c, TNF-a and IL-2 co-expressing, polyfunctional CD4+ T
cell subset (Figure 2B). A considerable proportion of Ag85A-
specific T cells also expressed IFN-c alone. By comparison, BCG-
specific CD4 T cells predominantly expressed IFN-c alone. The
cytokine expression profiles of persistent Ag85A-specific CD4+ T
cells detected in previously vaccinated children and infants were
very similar, while BCG-specific CD4 T cells in these younger age
groups also predominantly expressed IFN-c alone (Figure 2C
and D). We did not observe a marked effect of underlying M.tb
infection on this cytokine expression profile; the same polyfunc-
tional and IFN-c+ cells dominated the Ag85A-specific response
when M.tb-infected donors were excluded (Figure S2A).
Longitudinal analysis of the dominant IFN-c, TNF-a and IL-2
expressing, polyfunctional CD4+ T cell subset in adolescents,
children and infants confirmed the findings made by ELISpot
assay: responses detected after long-term follow-up were still
Figure 1. Longitudinal tracking of Ag85A-specific IFN-c ELISPOT responses in subjects vaccinated with MVA85A 3 to 6 years ago.
Red data points denote measurements from individuals who became infected with M.tb since completion of the original clinical trial. M.tb infection
was defined as conversion to a positive IFN-c ELISpot assay response to ESAT-6/CFP-10. Frequencies of IFN-c spot forming cells (SFC) detected before
vaccination and at the last time point after MVA85A vaccination were compared using the Wilcoxon signed rank test. Blue p-values denote
comparison of data from all individuals, while red p-values denote comparison of M.tb-uninfected (negative responders to ESAT-6/CFP-10) individuals
only. (A–D) Longitudinal tracking of Ag85A-specific T cell responses in adults (A, n = 17), adolescents (B, n = 9), children (C, n = 15) and infants (D,
n = 27), who received 56107 plaque forming units (pfu) of MVA85A. (E) Comparison of Ag85A-specific IFN-c ELISPOT responses in subjects who were
vaccinated more than 3 years ago with different doses of MVA85A as infants, or who received the placebo vaccine, Prevenar (n = 24 for Group 1,
n = 27 for Group 2; n = 24 for Group 3 and n= 23 for the placebo Group). The overall effect was calculated using the Kruskal-Wallis test, while
responses in each dose group were compared to the placebo group using the Mann-Whitney U test. Median and IQR IFN-c ELISPOT response values
are shown in Table S1.
doi:10.1371/journal.pone.0087340.g001
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Figure 2. Characterization of Ag85A-specific CD4 T cell Th1 cytokine expression patterns after long-term follow-up, 3–5 years after
MVA85A vaccination. (A) Representative gating of CD4 T cell expression of IFN-c, IL-2, TNF-a and/or IL-17 in blood left unstimulated, or stimulated
with BCG or Ag85A peptide pool, collected 1,187 days post-vaccination from a single participant who was 5 months old when originally vaccinated.
(B–E) Frequencies of cytokine-expressing Ag85A or BCG-speciific CD4 T cells were measured by whole blood intracellular cytokine staining assay in
adolescents (B), children (C) and infants (D and E). Cytokine expression patterns in adolescents and children who acquired M.tb-infection and those
who remained uninfected were not different (data not shown); all individuals, irrespective of M.tb-infection status are shown in B (n = 9) and C
(n = 16). Cytokine expression patterns in all infants (D and E, n = 15, 11, 12 and 11 for groups 1, 2, 3 and placebo respectively) were also not
Durable Th1 Responses with MVA85A
PLOS ONE | www.plosone.org 6 February 2014 | Volume 9 | Issue 2 | e87340
significantly higher than those detected before vaccination
(Figure S2 B–D).
We also sought to characterise cytokine expression profiles of
antigen-specific CD8+ T cells by flow cytometry. However, as
previously reported [17,22–24], Ag85A-specific CD8+ T cells
were mostly undetectable, or frequencies were too low to
characterise, in participants from all study groups (data not
shown).
Persistent Ag85A-specific CD4+ T cells predominantly
express an effector memory phenotype
Given the persistence of MVA85A-induced CD4+ T cells, we
sought to determine the memory phenotype of the Ag85A-specific
memory response. Long-lived central memory CD4+ cells
typically express high levels of CCR7, which endows these
CD45RA2 memory cells with lymph node homing capacity
[28]. By contrast, effector memory cells have lost expression of
CCR7, reside in the periphery and migrate to sites of infection.
Th1 cytokine-expressing Ag85A-specific and BCG-specific mem-
ory CD4+ T cells from all age groups were virtually exclusively
CD45RA-negative (Figure 3). Ag85A-specific CD4+ cells dis-
played either a CCR7+CD45RA2 central memory or
CCR72CD45RA2 effector memory phenotype in adolescents
and children (Figure 3B and C), while in infants the specific
response predominantly displayed a CCR72CD45RA2 effector
memory phenotype (Figure 3D). The latter phenotype was very
similar to BCG-specific Th1 cytokine-expressing CD4+ T cells
from infants, which also predominantly displayed an effector
memory phenotype (Figure 3E). Underlying M.tb infection had
no marked effect on the memory phenotypes of these cytokine-
expressing Ag85A-specific CD4+ T cells in any of the groups (data
not shown).
Highly durable Ag85A-specific T cell responses in ARV-
treated, but not untreated, HIV-positive vaccinees
We also determined if MVA85A-induced immune responses
persisted in participants of the TB011 trial, which was conducted
in M.tb-infected, HIV-infected, co-infected persons and HIV-
infected persons on successful ART [24]. Response magnitudes
detected by IFN-c ELISpot assay after long-term follow-up of
these 4 study groups were compared with those detected before
MVA85A vaccination. Frequencies of Ag85A-specific IFN-c-
expressing T cells in MVA85A vaccinated M.tb-infected (Group
1) or HIV-infected (Group 2) adults did not persist at magnitudes
higher than those detected before vaccination (Figure 4A and B
and Table S1). By contrast, Ag85A-specific response magnitudes
persisted at levels exceeding pre-vaccination levels in the M.tb/
HIV co-infected group (Group 3) and, in the ARV-treated, HIV-
positive group (Group 4; Figure 4C and D and Table S1).
Notably, Ag85A-specific T cells at long-term follow-up in
untreated HIV-infected participants were largely undetectable
(Figure 4B). These persons were not on ARV at the time of
vaccination because their CD4 counts exceeded 350 cells/mm3. In
contrast to the long-term memory responses, similar frequencies of
Ag85A-specific responses were detected during the first month
after MVA85A vaccination in the untreated and ARV-treated
HIV-infected groups (Figure 4B and D).
Next, we characterised the cytokine expression profile of
persistent Ag85A-specific CD4 T cells in participants of the
TB011 trial. No marked differences in cytokine expression
patterns of Ag85A-specific T cells detected 2–5 years after
MVA85A vaccination were observed between the 4 groups
(Figure S3). As observed for the other participant groups
(Figure 2), Ag85A-specific T cells predominantly resided in the
IFN-c, TNF-a and IL-2 co-expressing, polyfunctional CD4+ T
cell subset, while cells expressing IFN-c only were also observed
(Figure S3).
High frequencies of Ag85A-specific T cells during the
early response predict long-term persistence
Finally, we sought to determine if frequencies of specific T cells
during the first few months after MVA85A vaccination were
associated with specific T cell frequencies that persisted for years
after vaccination. We reasoned that such associations would
indicate whether early T cell response magnitudes predict long-
term persistence, suggesting that expensive and time-consuming
long-term follow-up of vaccinees may not be necessary. We
restricted these analyses to the TB014 infant groups, since the
limited sample sizes of the other age groups did not allow definitive
analyses. Frequencies of Ag85A-specific IFN-c-expressing T cells
detected 84 days after vaccination with 56107 pfu of MVA85A
correlated directly with those detected .1000 days after vaccina-
tion (Figure 5A). Significant, direct correlations between persis-
tent Ag85A-specific T cells responses and those measured 28, 84
and 168 days after MVA85A vaccination were observed in all 3
infant groups (Figure 5B–D). Responses measured 84 and 168
days post-vaccination most strongly correlated with frequencies of
Ag85A-specific T cells detected .1000 days after vaccination,
while pre-vaccination responses to Ag85A correlated poorly or not
at all.
Discussion
The aim of vaccination is to induce long-lasting adaptive
immune responses that mediate rapid and effective anti-microbial
immunity in the event of future pathogen exposure. To assess
long-term health of vaccinees and longevity of memory T cell
responses induced by a heterologous BCG-prime, MVA85A-boost
vaccination strategy, we performed a follow-up of individuals who
received a single MVA85A vaccination 2–6 years ago.
No major medical events or health-related issues that may relate
to MVA85A were reported or discovered in any of the vaccinees.
This was not unexpected, given previous experience that
MVA85A is generally well tolerated; no vaccine-related serious
adverse events have to date been reported in any of the open-label
trials [17,22–24]. Sample sizes were too small to definitively
evaluate the significance of the reported cases of TB in this
population, which resides in a setting of very high exposure to TB.
Both cases of TB recorded in adults were in HIV-positive
individuals, a group with an extremely high annual risk of TB
disease [29]. We also observed several conversions to positive
TST, and/or positive ELIspot responses to ESAT-6/CFP-10,
during the follow-up period. New M.tb infection is not unexpected
in this high burden setting and participant numbers were too small
and study designs not appropriate to assess how MVA85A
vaccination may have an impact on M.tb infection. The TST
conversion rate of 8/103 (7.8%) observed in participants
previously vaccinated as infants was lower than the recorded
Quantiferon conversion rate of 163/2253 (7.2%) in a recent Phase
significantly different. For all box and whisker plots, horizontal lines represent medians, boxes represent the IQR and whiskers represent the range for
each group of participants.
doi:10.1371/journal.pone.0087340.g002
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IIb efficacy trial of MVA85A in infants at this site [26]. Regardless,
no vaccine efficacy against M.tb infection was observed in that
study.
We report remarkable persistence of MVA85A-induced Ag85A-
specific CD4+ T cell responses in healthy, HIV-uninfected adults,
adolescents, children and infants. Induction of such long-lived T
cell responses is consistent with the finding that poxvirus-specific
Figure 3. Memory phenotype of highly persistent Ag85A-specific CD4 T cells. (A) Representative flow cytometry overlay plots, from a
MVA85A-vaccinated child, showing CD45RA and CCR7 co-expression patterns by the entire CD4 T cell subset (blue) and Ag85A-specific CD4 T cells
co-expressing IFN-c, TNF-a and IL-2 (black dots) after in vitro stimulation with Ag85A peptides, live BCG or PHA. (B–D) Proportions of cytokine-
expressing Ag85A-specific CD4 T cells expressing the indicated combination of CD45RA and CCR7, measured 3–5 years after MVA85A vaccination in
adolescents (B, n = 9), children (C, n = 16) and infants (D, n = 15, 11 and 12 for groups 1, 2 and 3, respectively). (E) Proportions of cytokine-expressing
BCG-specific CD4 T cells expressing the indicated combination of CD45RA and CCR7 in infants (n = 15, 11 and 12 for groups 1, 2 and 3, respectively).
For all box and whisker plots, horizontal lines represent medians, boxes represent the IQR and whiskers represent the range for each group of
participants.
doi:10.1371/journal.pone.0087340.g003
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CD4+ T cells were detected decades after DryVax vaccination
against smallpox [30]. Our data are congruent with and extend
those reported by Odutola et al., who observed durable T cell
responses to MVA85A vaccination up to fourteen months post-
vaccination in Gambian infants [20]. Long-term durability of
immune responses has only been described for one other novel TB
vaccine in preclinical studies [31] and one in clinical trials [32]. It
is important to perform extended follow-up to measure longevity
of vaccine-induced immunity, since vaccines should ideally
provide protection against pathogen exposure for many years. A
gradual attrition of mycobacteria-specific T cells has been
hypothesised to underlie the waning of BCG-induced protection
against pulmonary TB [8]. In light of this hypothesis, the
durability of MVA85A-induced Ag85A-specific memory responses
could be interpreted as a highly favourable outcome. However, we
recently reported that MVA85A vaccination afforded no en-
hancement in protective efficacy against TB disease or M.tb
infection in infants previously vaccinated with BCG, when given as
a heterologous boost vaccine [26]. The reasons underlying the lack
of efficacy over and above newborn BCG vaccination in this infant
trial are not known and are currently under scrutiny. Regardless,
given our present results on response durability, Ag85A-specific
CD4+ T cell responses would have persisted well beyond the
clinical follow-up period in the phase IIb efficacy trial. This
suggests that attrition of Ag85A-specific memory T cell responses
is unlikely to underlie the lack of vaccine protection against TB. It
is possible that the different cytokine expression profile of Ag85A-
specific (mostly IFN-c+TNF-a+IL-2+) and BCG-specific (mostly
IFN-c+ alone) CD4+ T cell responses may confer differential
immunity. Many investigators have hypothesized that polyfunc-
tionality may be a favourable property of the T cell response (ref
5). However, the predominantly monofunctional IFN-c+ CD4+ T
cell response induced by BCG, which is known to confer at least
partial efficacy against TB, provides data against this hypothesis.
Many other factors including the choice of antigen, magnitude,
tissue location, function and/or phenotype of the induced T cell
response, and/or epidemiological or clinical factors which may
include route and/or age of administration, dose of the vaccine
and the high rate of M.tb transmission in the trial population may
underlie the lack of vaccine-induced protection [26,33].
Our results from untreated HIV-infected persons showed that
Ag85A-specific CD4+ T cells were mostly undetectable 3–5 years
after MVA85A vaccination. These persons were not on ARV at
the time of vaccination because their CD4+ T cell counts exceeded
350 cells/mm3 at that time. By contrast, HIV-infected persons
who were on successful ARV when they received MVA85A had
readily detectable Ag85A-specific CD4+ T cells at their long-term
follow-up visit, at levels exceeding those detected pre-vaccination.
These results suggest that ARV may preserve or restore
mechanisms required for induction of long-term T cell memory,
which appear to be dysfunctional in untreated HIV infection, even
at CD4+ T cell counts exceeding 350 cells/mm3. Our data
support the recent recommendation to increase the CD4+ T cell
count at which ARV should be initiated from 350 to 500 cells/
mm3 [34].
Interestingly, similar frequencies of early effector Ag85A-specific
responses were detected during the first month after MVA85A
vaccination in persons with untreated and ARV-treated HIV-
Figure 4. Longitudinal tracking of Ag85A-specific IFN-c ELISPOT responses in M.tb-infected and/or HIV-infected subjects, who were
vaccinated with MVA85A 2 to 6 years ago as part of the TB011 trial [24]. (A) M.tb-infected, HIV-negative individuals (n = 11); (B) M.tb-
uninfected, HIV-infected individuals (n = 8); (C)M.tb and HIV-co-infected individuals (n = 9); (D) HIV-infected individuals on successful ART (irrespective
of M.tb-infection status, n = 9). Frequencies of IFN-c spot forming cells (SFC) detected before vaccination and at the last time point after MVA85A
vaccination were compared using the Wilcoxon signed rank test. Median and IQR IFN-c ELISPOT response values are shown in Table S1.
doi:10.1371/journal.pone.0087340.g004
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infection. This suggests that HIV-associated immune dysfunction
may not affect acute effector responses as markedly as its
detrimental impact on memory function.
Ag85A-specific CD4+ T cells detected after long-term follow-up
expressed surface markers consistent with either
CD45RA2CCR7+ central memory and CD45RA2CCR72
effector memory phenotypes. We expected persistence of vac-
cine-induced specific CD45RA2CCR7+ central memory T cells,
given the well-described prominence of this long-lived memory
subset in scenarios of cleared infections or vaccination [28], but
observed an age-specific difference. In older individuals Ag85A-
specific CD4+ T cells displayed a mixed central and effector
memory phenotype whereas in infants these cells predominantly
displayed an effector memory phenotype, which was similar to
BCG-specific CD4+ T cells. Sort lived effector memory cells with
immediate effector function are typically observed during the peak
of the immune response, or in the context of persistent antigen
load [28]. Our finding that the memory phenotype of Ag85A-
specific CD4+ T cells was not significantly different in M.tb-
infected and uninfected persons suggests that Ag85A-specific
CD4+ T cell phenotypes are not overtly sensitive to persistent M.tb
antigen load. Interestingly, induction and maintenance of effector
memory T cells, by chronic antigen stimulation, has been
proposed as a vaccination strategy against chronic infections
[35], including M.tb. Since effector cells preferentially home to
peripheral sites of inflammation such as the lung, and possess
immediate effector functions, these cells are hypothesised to confer
better protection against M.tb than central memory T cells. The
partially protective effect of murine BCG vaccination against M.tb
is consistent with this: BCG establishes a persistent infection in
mice [36] and thus maintains a population of effector memory T
cells [37].
Our study had a number of limitations. We used different cut-
off values of TST induration to define a positive TST in
Figure 5. Early MVA85A-induced Ag85A-specific T cell responses predict the level of persisting Ag85A-specific T cell responses. (A)
Representative Spearman correlation analysis of the frequencies of Ag85A-specific T cells detected by IFN-c ELISpot assay on day 84 post-vaccination
and more than 3 years post-vaccination in infants who received 56107 pfu of MVA85A. (B–D) Plots showing the Spearman r values obtained from
correlation analyses between the frequencies of Ag85A-specific T cell responses detected after long-term follow-up (more than 1000 days post-
vaccination), and those detected before MVA85A vaccination (day 0), or at 7, 28, 84 and 168 days MVA85A vaccination. Blue bars denote Spearman r
values with a p-value above 0.05, orange bars denote p-values between 0.05 and 0.01 and red bars denote p-values below 0.01. (B) Infants who
received 2.56107 pfu of MVA85A; (C) Infants who received 56107 pfu of MVA85A; (D) Infants who received 16108 pfu of MVA85A.
doi:10.1371/journal.pone.0087340.g005
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participants who were previously enrolled into the TB008 trial and
those who were previously enrolled into trials TB011 and TB014.
The reason for this was based on our decision to apply the
methods used in the previously completed trials, in which different
TST induration cut-off values were applied. Regardless, identifi-
cation of M.tb-infected participants by TST correlated well with
identification of these participants by IFN-c-expressing T cell
responses to ESAT-6/CFP-10, measured by ELISpot assay. We
are therefore confident that these technical factors have not
affected our results to a significant degree.
Differences in intercurrent acquisition rates of M.tb-infection in
different age groups limited our analyses of age-specific immune
responses. For example, most adolescents (7 out of 9) had acquired
M.tb-infection, while the majority of infants did not. Another
limitation was the absence of placebo control groups in the TB008
and TB011 trials, which precluded comparison of antigen-specific
T cell response durability in vaccinated and unvaccinated groups.
However, data from the infant trial suggests placebo responses to
Ag85A peptides would have been at the baseline level. Our
experience highlights the value of a placebo group even in small
phase I and II trials.
In summary, MVA85A induces remarkably durable Ag85A-
specific T cell responses in immunocompetent persons. However,
no vaccine efficacy was observed in a Phase IIb efficacy trial of
MVA85A conducted in infants from the same geographic area
and study population [26]. Taken together, our work suggests that
durability of BCG-induced Ag85A-specific T cell response, which
was significantly augmented by MVA85A vaccination, is not
sufficient to enhance BCG-induced protection against TB in
infants.
Supporting Information
Figure S1 Flow cytometric analysis of MVA85A-induced
T cell cytokine production, measured by whole blood
intracellular cytokine staining. (A) Representative dotplots
illustrating the gating strategy used to identify CD4 and CD8 T
cells 1,187 days post-vaccination from a single participant who was
5 months old when originally vaccinated. Top plots, from left to
right, white cells from whole blood were acquired and small,
CD3+ T lymphocytes selected. Cell doublets were then excluded
using forward scatter-area and forward scatter-height parameters,
followed by selection of cells with consistent fluorescent signal
during acquisition time (time gate). (B) Selection of CD4 T cells by
first gating on CD8-negative cells, and then CD4+ T cells. This
strategy, in which cytokine-expressing cells are plotted against the
T cell marker, was used to ensure that downregulation of the CD4
or CD8 proteins by activated, cytokine+ T cells does not lead to
exclusion of cytokine-expressing cells. (C) Selection of CD8 T cells
by first gating on CD4-negative cells, and then CD8+ T cells.
(EPS)
Figure S2 (A) Frequencies of Ag85A-specific CD4 T cells
detected by intracellular cytokine staining in infants who remained
M.tb uninfected (n = 15, 11, 12 and 11 for groups 1, 2, 3 and
placebo respectively). (B–D) Longitudinal frequencies of Ag85A-
specific polyfunctional IFN-c+TNF-a+IL-2+ CD4 T cells in
adolescents (B), children (C) and (D) infants. P-values represent
a comparison between the pre-vaccination and long-term follow-
up responses, using the Mann-Whitney U test. For all box and
whisker plots, horizontal lines represent medians, boxes represent
the IQR and whiskers represent the range for each group of
participants.
(TIF)
Figure S3 Characterization of Ag85A-specific CD4 T cell
Th1 cytokine expression patterns after long-term follow-
up, 2–5 years after MVA85A vaccination in participants
of the TB011 trial. Frequencies of cytokine-expressing CD4 T
cells were measured by whole blood intracellular cytokine staining
assay. Red, M.tb-infected, HIV-negative individuals (n = 11);
Black, M.tb-uninfected, HIV-infected individuals (n = 8); Blue,
M.tb and HIV-co-infected individuals (n = 9); Green, HIV-infected
individuals on successful ART (irrespective of M.tb-infection status,
n = 8). For all box and whisker plots, horizontal lines represent
medians, boxes represent the IQR and whiskers represent the
range for each group of participants.
(EPS)
Table S1 Medians and interquartile ranges of Ag85A-
specific IFN-c Elispot responses.
(DOC)
Author Contributions
Conceived and designed the experiments: MT H. Mahomed MH TJS H.
McShane WAH. Performed the experiments: MT HG AKKL ES JEH TS.
Analyzed the data: MT ES JEH H. McShane H. Mahomed TJS WAH.
Wrote the manuscript: MT HG AKKL ES EJH SV WAH MH H.
McShane TJS.
References
1. World Health Organisation (2013) Global Tuberculosis Report 2013.
2. Dye C, Williams BG (2008) Eliminating human tuberculosis in the twenty-first
century. J R Soc Interface 5: 653–662.
3. Abu-Raddad LJ, Sabatelli L, Achterberg JT, Sugimoto JD, Longini IM Jr, et al.
(2009) Epidemiological benefits of more-effective tuberculosis vaccines, drugs,
and diagnostics. Proc Natl Acad Sci U S A 106: 13980–13985.
4. Kagina BM, Abel B, Scriba TJ, Hughes EJ, Keyser A, et al. (2010) Specific T cell
frequency and cytokine expression profile do not correlate with protection
against tuberculosis after bacillus Calmette-Guerin vaccination of newborns.
Am J Respir Crit Care Med 182: 1073–1079.
5. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A (2011) Immunological
biomarkers of tuberculosis. Nat Rev Immunol 11: 343–354.
6. Skeiky YA, Sadoff JC (2006) Advances in tuberculosis vaccine strategies. Nat
Rev Microbiol 4: 469–476.
7. Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, et al. (1995) The
efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the
prevention of tuberculosis: meta-analyses of the published literature. Pediatrics
96: 29–35.
8. Orme IM (2010) The Achilles heel of BCG. Tuberculosis (Edinb) 90: 329–332.
9. Cellerai C, Harari A, Vallelian F, Boyman O, Pantaleo G (2007) Functional and
phenotypic characterization of tetanus toxoid-specific human CD4+ T cells
following re-immunization. Eur J Immunol 37: 1129–1138.
10. Akondy RS, Monson ND, Miller JD, Edupuganti S, Teuwen D, et al. (2009) The
yellow fever virus vaccine induces a broad and polyfunctional human memory
CD8+ T cell response. J Immunol 183: 7919–7930.
11. Wrammert J, Miller J, Akondy R, Ahmed R (2009) Human immune memory to
yellow fever and smallpox vaccination. J Clin Immunol 29: 151–157.
12. Vordermeier HM, Villarreal-Ramos B, Cockle PJ, McAulay M, Rhodes SG, et
al. (2009) Viral booster vaccines improve Mycobacterium bovis BCG-induced
protection against bovine tuberculosis. Infect Immun 77: 3364–3373.
13. Verreck FA, Vervenne RA, Kondova I, van Kralingen KW, Remarque EJ, et al.
(2009) MVA.85A boosting of BCG and an attenuated, phoP deficient M.
tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus
macaques. PLoS One 4: e5264.
14. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, et al.
(2003) Enhanced immunogenicity and protective efficacy against Mycobacteri-
um tuberculosis of bacille Calmette-Guerin vaccine using mucosal administra-
tion and boosting with a recombinant modified vaccinia virus Ankara. J Immunol
171: 1602–1609.
15. Williams A, Goonetilleke NP, McShane H, Clark SO, Hatch G, et al. (2005)
Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against
tuberculosis in guinea pigs. Infect Immun 73: 3814–3816.
16. Brookes RH, Hill PC, Owiafe PK, Ibanga HB, Jeffries DJ, et al. (2008) Safety
and immunogenicity of the candidate tuberculosis vaccine MVA85A in West
Africa. PLoS One 3: e2921.
Durable Th1 Responses with MVA85A
PLOS ONE | www.plosone.org 11 February 2014 | Volume 9 | Issue 2 | e87340
17. Hawkridge T, Scriba TJ, Gelderbloem S, Smit E, Tameris M, et al. (2008)
Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy
adults in South Africa. J Infect Dis 198: 544–552.
18. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, et al. (2004)
Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts
BCG-primed and naturally acquired antimycobacterial immunity in humans.
Nat Med 10: 1240–1244.
19. Minassian AM, Rowland R, Beveridge NE, Poulton ID, Satti I, et al. (2011) A
Phase I study evaluating the safety and immunogenicity of MVA85A, a
candidate TB vaccine, in HIV-infected adults. BMJ Open 1: e000223.
20. Odutola AA, Owolabi OA, Owiafe PK, McShane H, Ota MO (2012) A new TB
vaccine, MVA85A, induces durable antigen-specific responses 14 months after
vaccination in African infants. Vaccine 30: 5591–5594.
21. Sander CR, Pathan AA, Beveridge NE, Poulton I, Minassian A, et al. (2009)
Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in
Mycobacterium tuberculosis-infected individuals. Am J Respir Crit Care Med
179: 724–733.
22. Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, et al. (2010)
Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is
safe in adolescents and children, and induces polyfunctional CD4+ T cells.
Eur J Immunol 40: 279–290.
23. Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, et al. (2011)
Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-
vaccinated infants. J Infect Dis 203: 1832–1843.
24. Scriba TJ, Tameris M, Smit E, van der Merwe L, Hughes EJ, et al. (2012) A
phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV2 and/or
Mycobacterium tuberculosis-infected adults. Am J Respir Crit Care Med 185:
769–778.
25. Whelan KT, Pathan AA, Sander CR, Fletcher HA, Poulton I, et al. (2009)
Safety and immunogenicity of boosting BCG vaccinated subjects with BCG:
comparison with boosting with a new TB vaccine, MVA85A. PLoS One 4:
e5934.
26. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, et al. (2013)
Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously
vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet.
27. Geldenhuys H, Verver S, Surtie S, Hatherill M, van Leth F, et al. (2010) The
tuberculin skin test: a comparison of ruler and calliper readings. Int J Tuberc
Lung Dis 14: 1266–1271.
28. Sallusto F, Geginat J, Lanzavecchia A (2004) Central memory and effector
memory T cell subsets: function, generation, and maintenance. Annu Rev
Immunol 22: 745–763.
29. Lawn SD, Myer L, Edwards D, Bekker LG, Wood R (2009) Short-term and
long-term risk of tuberculosis associated with CD4 cell recovery during
antiretroviral therapy in South Africa. AIDS 23: 1717–1725.
30. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, et al. (2003) Cutting
edge: long-term B cell memory in humans after smallpox vaccination. J Immunol
171: 4969–4973.
31. Lindenstrom T, Agger EM, Korsholm KS, Darrah PA, Aagaard C, et al. (2009)
Tuberculosis subunit vaccination provides long-term protective immunity
characterized by multifunctional CD4 memory T cells. J Immunol 182: 8047–
8055.
32. van Dissel JT, Arend SM, Prins C, Bang P, Tingskov PN, et al. (2010) Ag85B-
ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium
tuberculosis specific T cell responses in naive human volunteers. Vaccine 28:
3571–3581.
33. Dye C, Fine PE (2013) A major event for new tuberculosis vaccines. Lancet 381:
972–974.
34. World Health Organisation (2013) Consolidated guidelines on the use of
retroviral drugs for treating and preventing HIV infection,. 272.
35. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, et al. (2011)
Profound early control of highly pathogenic SIV by an effector memory T-cell
vaccine. Nature 473: 523–527.
36. Mittrucker HW, Steinhoff U, Kohler A, Krause M, Lazar D, et al. (2007) Poor
correlation between BCG vaccination-induced T cell responses and protection
against tuberculosis. Proc Natl Acad Sci U S A 104: 12434–12439.
37. Kaveh DA, Bachy VS, Hewinson RG, Hogarth PJ (2011) Systemic BCG
immunization induces persistent lung mucosal multifunctional CD4 T(EM) cells
which expand following virulent mycobacterial challenge. PLoS One 6: e21566.
Durable Th1 Responses with MVA85A
PLOS ONE | www.plosone.org 12 February 2014 | Volume 9 | Issue 2 | e87340
